The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Advancements in oligometastatic GI cancer management
Nataliya Uboha, MD, PhD, University of Wisconsin Carbone Cancer Center, Madison, WI, emphasizes the need for data and clinical trials in the management of oligometastatic gastrointestinal (GI) cancers. She highlights significant advancements in both local regional therapies, such as ablation and stereotactic ablative radiotherapy (SBRT), and systemic treatments. The incorporation of immunotherapy and upcoming use of new targeted agents like zolbetuximab show promise in controlling local and micrometastatic disease. Dr Uboha suggests that with improved systemic treatments and enhanced control of micrometastatic disease, a more aggressive approach to treating isolated metastatic sites becomes justifiable, considering the overall ability to address the systemic burden of disease. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
